
Partner
Juvena Therapeutics is a platform biotech that develops medicines from proteins secreted by stem cells. Co-founder and CSO Jeremy O’Connell directs R&D strategy across muscle, bone and cartilage, and inflammation.
Challenge
Juvena finds targets across diverse fields and can’t staff specialists for every protein. Jeremy needs to understand each one well enough to decide what to pursue.
Approach
Jeremy brings the criteria, and Studio does the research. For every target, it layers competitive, clinical, and biological evidence from trials, patents, papers, genetics, and deals, and explains how each one measures up.
Outcome
Jeremy does a research team’s work for Juvena’s whole pipeline in Studio, from portfolio triage to program biology. In one run, he triaged 21 unfamiliar targets in about an hour and sent the best into go/no-go review.
“We do a lot of first-in-class work, so for every new target we need to know an incredible amount of information quickly. Sleuth kills everything that’s not obviously good, so we can spend our time on the few that might be a gold mine. In minutes, it’s another FTE worth of information coming back to me.”

Jeremy O’Connell, PhD
Co-founder and Chief Scientific Officer, Juvena Therapeutics

Jeremy moved his landscapes and target reviews from PatSnap to Studio. Studio puts patent-only programs in the same landscape as everything else, with the patents behind each one and the deals around them.
When Jeremy has put the same question to Gemini and to Studio, Studio has come out ahead. Gemini answers from the open web; Studio answers from trial registries, patents, and papers, and shows him which ones.
Jeremy’s discovery work turned up 21 targets no one at Juvena had studied. He set up a Studio project for each, and in about an hour Studio built every one a dataset of competitive, clinical, and biological evidence from trial registries, patents, papers, genetic databases, and deals, judged against his criteria.


Then Jeremy went deeper on the 12 that made it through, asking Studio sharper questions of his own, like whether the biology holds up in human muscle or which papers to trust when they disagree. For each answer, Studio searched a knowledge base of 1M+ trials, 150K+ drugs, 300K+ patents, and the published literature, and showed the reasoning behind every score.

The top three went into Juvena’s go/no-go review.